Free Trial
NASDAQ:IMMX

Immix Biopharma Q2 2024 Earnings Report

Immix Biopharma logo
$2.24 +0.29 (+14.82%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immix Biopharma EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Immix Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immix Biopharma Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Sunday, August 11, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Immix Biopharma's Q1 2025 earnings is scheduled for Monday, August 11, 2025

Earnings Documents

Immix Biopharma Earnings Headlines

Immix Biopharma Inc.
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Immix Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

View Immix Biopharma Profile

More Earnings Resources from MarketBeat